AbbVie annual total liabilities
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Total Liabilities Growth & History (ABBV)
AbbVie's total liabilities was $137.19B for fiscal 2025.
View full AbbVie company overviewAbbVie annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $137.19B | $5.39B | +4.09% |
| 2024 | 2024-12-31 | $131.80B | $7.48B | +6.02% |
| 2023 | 2023-12-31 | $124.31B | $2.80B | +2.30% |
| 2022 | 2022-12-31 | $121.52B | −$9.57B | −7.30% |
| 2021 | 2021-12-31 | $131.09B | −$6.38B | −4.64% |
| 2020 | 2020-12-31 | $137.47B | $40.18B | +41.30% |
| 2019 | 2019-12-31 | $97.29B | $29.49B | +43.50% |
| 2018 | 2018-12-31 | $67.80B | $2.11B | +3.21% |
| 2017 | 2017-12-31 | $65.69B | $4.23B | +6.88% |
| 2016 | 2016-12-31 | $61.46B | $12.36B | +25.17% |
| 2015 | 2015-12-31 | $49.10B | $23.33B | +90.54% |
| 2014 | 2014-12-31 | $25.77B | $1.06B | +4.31% |
| 2013 | 2013-12-31 | $24.71B | −$2.65B | −9.69% |
| 2012 | 2012-12-31 | $27.36B | — | — |
AbbVie quarterly total liabilities
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $141.00B | $3.68B | +2.68% |
| Q1 2026 | 2026-03-31 | $143.07B | $8.37B | +6.22% |
| Q4 2025 | 2025-12-31 | $137.19B | $5.39B | +4.09% |
| Q3 2025 | 2025-09-30 | $136.50B | −$854.0M | −0.62% |
| Q2 2025 | 2025-06-30 | $137.32B | $2.20B | +1.63% |
| Q1 2025 | 2025-03-31 | $134.70B | −$6.12B | −4.35% |
| Q4 2024 | 2024-12-31 | $131.80B | $7.48B | +6.02% |
| Q3 2024 | 2024-09-30 | $137.35B | $13.26B | +10.68% |
| Q2 2024 | 2024-06-30 | $135.12B | $12.65B | +10.33% |
| Q1 2024 | 2024-03-31 | $140.83B | $19.59B | +16.15% |
| Q4 2023 | 2023-12-31 | $124.31B | $2.80B | +2.30% |
| Q3 2023 | 2023-09-30 | $124.09B | −$1.21B | −0.96% |
| Q2 2023 | 2023-06-30 | $122.47B | −$6.03B | −4.69% |
| Q1 2023 | 2023-03-31 | $121.24B | −$5.66B | −4.46% |
| Q4 2022 | 2022-12-31 | $121.52B | −$9.57B | −7.30% |
| Q3 2022 | 2022-09-30 | $125.30B | −$9.98B | −7.38% |
| Q2 2022 | 2022-06-30 | $128.50B | −$6.88B | −5.08% |
| Q1 2022 | 2022-03-31 | $126.90B | −$9.87B | −7.22% |
| Q4 2021 | 2021-12-31 | $131.09B | −$6.38B | −4.64% |
| Q3 2021 | 2021-09-30 | $135.28B | $949.0M | +0.71% |
| Q2 2021 | 2021-06-30 | $135.38B | $580.0M | +0.43% |
| Q1 2021 | 2021-03-31 | $136.77B | $38.15B | +38.69% |
| Q4 2020 | 2020-12-31 | $137.47B | $40.18B | +41.30% |
| Q3 2020 | 2020-09-30 | $134.33B | $66.67B | +98.52% |
| Q2 2020 | 2020-06-30 | $134.80B | $69.09B | +105.15% |
| Q1 2020 | 2020-03-31 | $98.61B | $34.02B | +52.67% |
| Q4 2019 | 2019-12-31 | $97.29B | $29.49B | +43.50% |
| Q3 2019 | 2019-09-30 | $67.67B | −$1.42B | −2.05% |
| Q2 2019 | 2019-06-30 | $65.71B | $692.0M | +1.06% |
| Q1 2019 | 2019-03-31 | $64.59B | −$1.19B | −1.81% |
| Q4 2018 | 2018-12-31 | $67.80B | $2.11B | +3.21% |
| Q3 2018 · Sep 30 | 2018-09-30 | $69.08B | $6.93B | +11.15% |
| Q2 2018 | 2018-06-30 | $65.02B | $4.03B | +6.61% |
| Q1 2018 | 2018-03-31 | $65.79B | $5.12B | +8.44% |
| Q4 2017 | 2017-12-31 | $65.69B | $4.23B | +6.88% |
| Q3 2017 | 2017-09-30 | $62.15B | $2.00B | +3.32% |
| Q2 2017 | 2017-06-30 | $60.98B | −$586.0M | −0.95% |
| Q1 2017 | 2017-03-31 | $60.67B | $11.59B | +23.61% |
| Q4 2016 | 2016-12-31 | $61.46B | $12.36B | +25.17% |
| Q3 2016 | 2016-09-30 | $60.16B | $10.19B | +20.39% |
| Q2 2016 | 2016-06-30 | $61.57B | $13.22B | +27.34% |
| Q1 2016 | 2016-03-31 | $49.08B | $23.75B | +93.81% |
| Q4 2015 | 2015-12-31 | $49.10B | $23.33B | +90.54% |
| Q3 2015 | 2015-09-30 | $49.97B | $26.16B | +109.87% |
| Q2 2015 | 2015-06-30 | $48.35B | $24.52B | +102.93% |
| Q1 2015 | 2015-03-31 | $25.32B | $1.36B | +5.68% |
| Q4 2014 | 2014-12-31 | $25.77B | $1.06B | +4.31% |
| Q3 2014 | 2014-09-30 | $23.81B | −$866.0M | −3.51% |
| Q2 2014 | 2014-06-30 | $23.83B | −$525.0M | −2.16% |
| Q1 2014 | 2014-03-31 | $23.96B | −$252.0M | −1.04% |
| Q4 2013 | 2013-12-31 | $24.71B | −$2.65B | −9.69% |
| Q3 2013 | 2013-09-30 | $24.68B | — | — |
| Q2 2013 | 2013-06-30 | $24.35B | — | — |
| Q1 2013 | 2013-03-31 | $24.21B | — | — |
| Q4 2012 | 2012-12-31 | $27.36B | — | — |
AbbVie total liabilities trends
Over the last five fiscal years, AbbVie's total liabilities decreased from $137.47B to $137.19B, a change of −$280.0M. The latest reported quarter, Q2 2026, shows $141.00B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...